Compositions and methods for counteracting effects of reactive oxygen species and free radicals
View Patent ↗Peptide compounds and methods for upregulating expression of a gene encoding an antioxidative enzyme, such as superoxide dismutase or catalase, to counteract harmful oxidative effects of reactive oxygen species and other free radicals are described. The peptide compounds may be used to treat or prevent diseases and conditions characterized by undesirable elevation of reactive oxygen species and other free radicals, to upregulate AP-1 gene expression, and to treat pain. The peptide compounds may be used as components of pharmaceuticals and dietary supplements.
1. A method of treating an ischemic injury in a subject, the method comprising administering to the subject a peptide compound, wherein the amino acid sequence of the peptide compound is Asp Gly Asp, Asp Gly, Thr Val Ser, or Glu Ala, wherein the peptide compound is administered in an amount effective to treat the ischemic injury, wherein the peptide compound comprises an amino terminal capping group and/or a carboxy terminal capping group.
2. The method of claim 1 , wherein the amino terminal capping group is a lipoic acid moiety (Lip).
3. The method of claim 1 , wherein the ischemic injury is a reperfusion injury.
4. The method of claim 1 wherein the ischemic injury results from a stroke.
5. The method of claim 1 , wherein the ischemic injury is a myocardial infarction.
6. The method of claim 1 , wherein the ischemic injury results from an occlusion.
7. The method of claim 1 , wherein the ischemic injury results from a heart attack.
8. The method of claim 1 , wherein the ischemic injury is a drug-induced injury.
9. The method of claim 2 , wherein the peptide compound is [Lip]-Asp Gly.
10. The method of claim 2 , wherein the peptide compound is [Lip]-Glu Ala.
11. The method of claim 2 , wherein the peptide compound is [Lip]-Asp Gly Asp.
12. The method of claim 2 , wherein the peptide compound is [Lip]-Thr Val Ser.
13. A method for reducing an elevated level of reactive oxygen species (ROS) and/or free radicals in a subject, the method comprising administering to the subject a peptide compound, wherein the amino acid sequence of the peptide compound is Asp Gly Asp, Asp Gly, Thr Val Ser, or Glu Ala, wherein the peptide compound is administered in an amount effective to reduce the elevated level of ROS and/or free radicals in the subject, wherein the peptide compound comprises an amino terminal capping group and/or a carboxy terminal capping group.
14. The method of claim 13 , wherein the elevated level of ROS and/or free radicals is the result of an ischemic injury in the subject.
15. A method for treating an ischemic injury in a subject, the method comprising administering to the subject a peptide compound, wherein the amino acid sequence of the peptide compound is Glu Gly, Asp Gly Asp Gly Asp, Asp Ala (SEQ ID NO:4), or Asp Gly Asp Gly Asp Phe Ala (SEQ ID NO:6), wherein the peptide compound is administered in an amount effective to treat the ischemic injury in the subject, wherein the peptide compound comprises an amino terminal capping group and/or a carboxy terminal capping group.
16. A method for reducing an elevated level of reactive oxygen species (ROS) and/or free radicals in a subject, the method comprising administering to the subject a peptide compound, wherein the amino acid sequence of the peptide compound is Glu Gly, Asp Gly Asp Gly Asp (SEQ ID NO:4), Asp Ala, or Asp Gly Asp Gly Asp Phe Ala (SEQ ID NO:6), wherein the peptide compound is administered in an amount effective to reduce the elevated level of ROS and/or free radical in the subject, wherein the peptide compound comprises an amino terminal capping group and/or a carboxy terminal capping group.
17. A method for treating an ischemic injury in a subject, the method comprising administering to the subject a peptide compound that has the formula:
R1 Xaa1 Xaa2 Xaa3 R2,
wherein Xaa1 is Asp, Asn, Glu, Gln, Thr, or Tyr; Xaa2 is absent or any amino acid; Xaa3 is Asp, Asn, Glu, Thr, Ser, Gly, or Leu; R1 is absent or is an amino terminal capping group; R2 is absent or is a carboxy terminal capping group, and wherein the peptide compound comprises an amino terminal capping group and/or a carboxy terminal capping group.
18. A method for reducing an elevated level of reactive oxygen species (ROS) and/or free radicals in a subject, the method comprising administering to the subject a peptide compound that has the formula:
R1 Xaa1 Xaa2 Xaa3 R2,
wherein Xaa1 is Asp, Asn, Glu, Gln, Thr, or Tyr; Xaa2 is absent or any amino acid; Xaa3 is Asp, Asn, Glu, Thr, Ser, Gly, or Leu; R1 is absent or is an amino terminal capping group; R2 is absent or is a carboxy terminal capping group, and wherein the peptide compound comprises an amino terminal capping group and/or a carboxy terminal capping group.